Johnson & Johnson
JNJJohnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42nd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global.
Drugs in Pipeline
244
Phase 3 Programs
163
Upcoming Catalysts
4
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
5 upcoming, 1 past
FDA PDUFA Date Ziihera
For GEA. AI-extracted from news: Jazz reaffirms $4.25B-$4.5B 2026 revenue guidance while targeting an Aug. 25, 2026 PDUFA for Ziihera
Fast-detected from FDA RSS: FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
Source4 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How JNJ's past catalysts played out
oxycodone CR
Joint Diseases
Ustekinumab 90 mg SC q8w
Crohn's Disease
Group 1: Epoetin alfa
Myelodysplastic Syndromes
Lazertinib
Carcinoma, Non-Small-Cell Lung
PP6M
Schizophrenia
Etravirine
HIV Infections
Tapentadol (CG5503)
Arthralgia
Canagliflozin 300 mg
Diabetes Mellitus, Type 2
CONCERTA (OROS methylphenidate hydrochloride)
Attention Deficit Disorder With Hyperactivity
OROS hydromorphone HCl
Pain
Peginterferon-alpha (PegIFNα-2a)
Hepatitis C, Chronic
Decitabine 20 mg/m^2
Leukemia, Myeloid, Acute
MVA-BN-Filo
Hemorrhagic Fever, Ebola
Genetic: AAV5-hRKp.RPGR Intermediate Dose
X-Linked Retinitis Pigmentosa
Ad26.Mos4.HIV
Healthy
Icotrokinra
Crohn Disease
Remifentanil
Anesthesia
Pegylated interferon alfa-2a
Chronic Hepatitis C Virus (HCV) Infection
Sirukumab 50 mg
Depressive Disorder, Major
Guselkumab dose 1
Hidradenitis Suppurativa
Aticaprant
Depressive Disorder, Major
Milvexian
Acute Coronary Syndrome
Fentanyl 1-day transdermal patch (Titration Phase)
Pain
ER OROS paliperidone
Schizophrenia
Efgartigimod
Myasthenia Gravis
Erdafitinib
Advanced Solid Tumor
rivaroxaban 15 mg
Atrial Fibrillation
Group 2 ustekinumab 130 mg
Crohn's Disease
5-Flurouracil
Squamous Cell Carcinoma of Head and Neck
CNTO 1959 50 mg
Psoriasis
ExPEC9V
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
NUCYNTA
Pain
Paliperidone palmitate (R092670)
Schizophrenia
paliperidone palmitate injection
Schizophrenia
TAR-210
Non-Muscle Invasive Bladder Neoplasms
Vinflunine
Urothelial Cancer
Guselkumab Dose 2
Colitis, Ulcerative
PP3M 175 mg eq.
Schizophrenia
Ustekinumab IV
Colitis, Ulcerative
DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
HIV-1
Canagliflozin 100 mg
Diabetes Mellitus, Type 2
Ad26.ZEBOV
Ebola Virus Disease
Bendamustine hydrochloride
Chronic Lymphocytic Leukemia
R331333 (referred to as JNS024 ER or CG5503)
Pain
Genetic: AAV5-hRKp.RPGR
X-Linked Retinitis Pigmentosa
Efavirenz
Human Immunodeficiency Virus-type 1 Infection
Pegylated interferon alfa-2a (PegIFNα-2a)
Hepatitis C, Chronic
Golimumab
Arthritis, Juvenile
Guselkumab 100 mg
Psoriasis
Risankizumab
Crohn Disease
Nipocalimab
Arthritis, Rheumatoid
Telaprevir
Hepatitis C, Chronic
Pegylated interferon alpha-2a
Hepatitis C Virus Genotype-1
ustekinumab 45 mg
Arthritis, Psoriatic
Durogesic® (fentanyl transdermal drug delivery system)
Chronic Pain
Paliperidone ER OROS®
Schizophrenia
Canagliflozin
Diabetes Mellitus, Type 2
Abiraterone acetate
Prostate Neoplasms
Ad26.ZEBOV 5*10^10 viral particles (vp)
Healthy
Intravenous immunoglobulins (IVIG)
Thrombocytopenia, Neonatal Alloimmune
methylphenidate
Depressive Disorder, Major
Sirukumab
Arthritis, Rheumatoid
Daratumumab IV
Multiple Myeloma
Paliperidone extended release (ER)
Schizophrenia
Ad26.RSV.PreF-based Vaccine
Respiratory Syncytial Virus Prevention
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF
Respiratory Syncytial Viruses
D/C/F/TAF
Human Immunodeficiency Virus Type 1
Nesiritide
Heart Decompensation
Fumaric Acid Esters
Psoriasis
Temsirolimus
Mantle Cell Lymphoma
Sofosbuvir
Chronic Hepatitis C
Epo-alpha
Resuscitation
Tapentadol (CG5503) Extended Release (ER)
Pain
Rivaroxaban (Xarelto, BAY59-7939)
Venous Thromboembolism
Morphine
Hysterectomy
oxycodone
Osteoarthritis, Knee
Risperidone, long-acting injectable
Schizophrenia
risperidone; quetiapine
Bipolar Disorder
topiramate, propranolol
Migraine
Enoxaparin
Venous Thromboembolism
CG5503 IR
Bunionectomy
galantamine ER
Alzheimer's Disease
Test acetaminophen
Post-operative Dental Pain
CG 5503;tapentadol
Osteoarthritis
tapentadol (CG5503) ER
Low Back Pain
levofloxacin
Pneumonia
Rivaroxaban
Atrial Fibrillation
tapentadol (CG5503) Immediate Release IR
Low Back Pain
Acetaminophen/Naproxen Sodium Fixed Combination
Pain
Paliperidone extended-release
Bipolar Disorder
Risperdal Consta
Bipolar Disorder
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
Multiple Myeloma
paliperidone ER Oros
Schizophrenia
Gemcitabine with R115777
Pancreatic Neoplasms
Mebendazole
Healthy Volunteers
Dapoxetine
Erectile Dysfunction
F# 13418-148 Eye Drops
Ophthalmic Solutions
Rivaroxaban 2.5 mg
Acute Coronary Syndrome
Paliperidone ER
Schizophrenia
topiramate
Essential Tremor
doripenem
Pneumonia
norelgestromin + ethinyl estradiol
Contraception
Rabeprazole sodium 5 mg
Gastroesophageal Reflux
Tapentadol extended release (ER)
Diabetic Peripheral Neuropathy
Thalidomide
Multiple Myeloma
CG5503 IR;tapentadol
Arthralgia
Topiramate; Carbamazepine; Valproate
Epilepsy
levofloxacin; imipenem/cilastitin
Nosocomial Pneumonia
Pancrease MT 10.5, or MT 21
Exocrine Pancreatic Insufficiency
Colloidal Oatmeal Cream
Eczema
ivermectin
Lice Infestations
Paliperidone palmitate 25 mg eq.
Schizophrenia
JNJ-90301900 (NBTXR3)
Locally Advanced Head and Neck Squamous Cell Carcinoma
norelgestromin + ethinyl estradiol; mercilon
Contraception
Extended-release galantamine hydrobromide
Schizophrenia
Test naproxen sodium tablet
Post-operative Dental Pain
galantamine
Alzheimer's Disease
5% Minoxidil Topical Foam
Androgenetic Alopecia
Imonogas
Functional Dyspepsia
rabeprazole
Gastroesophageal Reflux Disease (GERD)
galantamine hydrobromide
Alzheimer Disease
Hydromorphone HCl
Pain
topiramate, phenytoin
Epilepsy
Paliperidone palmitate
Schizophrenia
norelgestromin + ethinyl estradiol; triphasil.
Contraception
doripenum
Urinary Tract Infections
acetaminophen extended release
Osteoarthritis
CG5503
Diabetic Neuropathy
Duragesic® (fentanyl) Therapeutic Transdermal System (TTS)
Chronic Pain
CG5503 IR; tapentadol
Osteoarthritis
5% Minoxidil
Alopecia
naproxen
Osteoarthritis, Hip
minoxidil
Androgenetic Alopecia
PDE5I (phosphodiesterase-5 inhibitor)
Erectile Dysfunction
Extended Release OROS® Paliperidone
Schizophrenia
acetaminophen Tablet
Post Operative Dental Pain
Paliperidone
Schizophrenia
Tipifarnib;Zarnestra; R115777
Acute Myeloid Leukemia
Epoetin alfa 3 times weekly /once weekly
Anemia
epoetin alfa
Chronic Kidney Disease
Prucalopride
Constipation
Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell
TAR-200
Non-Muscle Invasive Bladder Neoplasms
Levetiracetam
Epilepsy
Cilta-cel
Multiple Myeloma
Talquetamab
Multiple Myeloma
TMC435
Hepatitis C
JNJ-77242113
Plaque Psoriasis
Simeprevir
Hepatitis C Virus Infection
Fentanyl
Postherpetic Neuralgia
No treatment
Hepatitis C
JNJ-63723283
Multiple Myeloma
Guselkumab
Psoriasis
Daratumumab
Multiple Myeloma
Fulranumab 1 mg
Osteoarthritis
Ad26.COV2.S
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
Macitentan
Pulmonary Arterial Hypertension
Rilpivirine
HIV-1
Amivantamab
Carcinoma, Non-Small-Cell Lung
Sirukumab 100 mg
Arthritis, Rheumatoid
Seltorexant
Depressive Disorder, Major
Ustekinumab
Crohn Disease
Teclistamab
Multiple Myeloma
R228060
Major Depressive Disorder
Antipsychotic medication
Schizophrenia
Daratumumab 16 mg/kg (Part 1)
Multiple Myeloma
Escitalopram
Major Depressive Disorder
JNJ-90301900
Carcinoma, Non-Small-Cell Lung
Experimental Product 1% Colloidal Oatmeal Balm
Atopic Dermatitis
Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
Multiple Myeloma
JNJ16269110
Diabetes Mellitus, Type 2
Canagliflozin (JNJ-28431754)
Diabetes Mellitus, Type II
ibuprofen; pseudoephedrine HCl
Enuresis
RWJ-445380 100 mg
Rheumatoid Arthritis
Capmatinib
Carcinoma, Non-Small-Cell Lung
CNTO 1959
Palmoplantaris Pustulosis
Nesiritide (1+0.01)
Heart Failure, Congestive
Erdafitinib Intravesical Delivery System
Non-Muscle Invasive Bladder Neoplasms
Ad26.RSV.preF (1*10^11 vp)
Respiratory Syncytial Viruses
JNJ-40411813
Major Depressive Disorder
tapentadol HCl
Pain
Abiraterone
Prostate Cancer
ET743
Breast Neoplasms
JNJ-37822681
Schizophrenia
JNJ-64565111 Dose Level 1
Obesity and Diabetes Mellitus, Type 2
Canagliflozin 50 mg
Diabetes Mellitus, Type 2
JNJ-63623872
Influenza A Virus
AL-335
Hepatitis C, Chronic
R092670
Schizophrenia
JNJ-73763989
Hepatitis B, Chronic
Siltuximab
Multicentric Castleman's Disease
JNJ-40346527
Arthritis, Rheumatoid
JNJ-41443532
Diabetes Mellitus, Type 2
JNJ-64304500
Crohn Disease
JNJ-39588146 5 ng/kg/min
Heart Failure
tipifarnib (R115777)
Leukemia, Nonlymphocytic, Acute
JNJ39758979
Asthma
NNC0142-0002
Inflammation
RSV Vaccine
Healthy
NNC 0142-0000-0002
Inflammation
Imipenem/cilastatin
Pneumonia, Ventilator-Associated
JNJ-31001074
Attention Deficit Hyperactivity Disorder
T2-18C3 therapeutic antibody
Type 2 Diabetes
Tapentadol
Pain
Amivantamab IV
Advanced or Metastatic Colorectal Cancer
JNJ 40929837
Asthma
Glucocorticoids
Myositis
R209130
Schizophrenia
Ketoconazole
Neoplasm Metastases
CNTO 2476 3.0 x 10^5 cells
Visual Acuity
Fluarix
Healthy
R256918
Obesity
Apalutamide
Salivary Gland Neoplasms
ZARNESTRA, tipifarnib, R115777
Acute Myeloid Leukemia
VX-787 300 mg
Influenza A
Daratumumab Injection
Plasma Cell Disorder
JNJ-17166864
Allergic Rhinitis
Acetaminophen (ACE) (1000 mg)
Dental Pain
JNJ-81201887
Geographic Atrophy
Acetaminophen
Post Operative Analgesia
Olomorasib
Carcinoma, Non-Small-Cell Lung
Ad26.RSV.preF
Respiratory Syncytial Virus
VELCADE
Diffuse Large B-Cell Lymphoma
PROCRIT (Epoetin alfa)
Anemia
Cetrelimab
Urinary Bladder Neoplasms
sIPV
Healthy
Ad26.Mos.HIV
Healthy
MVA-Mosaic
Human Immunodeficiency Virus
JNJ-53718678
Respiratory Syncytial Virus Infections
Blink® Tears eye drops in a multidose bottle
Visual Acuity
TMC207 (bedaquiline)
Tuberculosis, Multidrug-Resistant
JNJ-42165279
Depressive Disorder
JNJ-42847922
Depressive Disorder, Major
440 mg naproxen sodium with 1000 mg acetaminophen
Pain
JNJ-26489112
Photosensitive Epilepsy
Atomoxetine 80 mg/d
Attention Deficit Hyperactivity Disorder
Acetaminophen/naproxen sodium Dose A
Pain
Investigational Lubricating Eye Drop in a Novelia® bottle
Dry Eye
JNJ-39220675
Allergic Rhinitis
Standard-of-care treatment
Systemic Lupus Erythematosus
Yondelis
Liposarcoma
Atazanavir (ATV) 300 mg
HIV Infections
JNJ 49095397
Chronic Obstructive Pulmonary Disease
ExPEC4V (4 : 4 : 4 : 4)
Healthy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
oxycodone CR | Phase 3 | Joint Diseases | - | - |
Ustekinumab 90 mg SC q8w | Phase 3 | Crohn's Disease | - | - |
Group 1: Epoetin alfa | Phase 3 | Myelodysplastic Syndromes | - | - |
Lazertinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
PP6M | Phase 3 | Schizophrenia | - | - |
Etravirine | Phase 3 | HIV Infections | - | - |
Tapentadol (CG5503) | Phase 3 | Arthralgia | - | - |
Canagliflozin 300 mg | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
CONCERTA (OROS methylphenidate hydrochloride) | Phase 3 | Attention Deficit Disorder With Hyperactivity | - | - |
OROS hydromorphone HCl | Phase 3 | Pain | - | - |
Peginterferon-alpha (PegIFNα-2a) | Phase 3 | Hepatitis C, Chronic | - | - |
Decitabine 20 mg/m^2 | Phase 3 | Leukemia, Myeloid, Acute | - | - |
MVA-BN-Filo | Phase 3 | Hemorrhagic Fever, Ebola | - | - |
Genetic: AAV5-hRKp.RPGR Intermediate Dose | Phase 3 | X-Linked Retinitis Pigmentosa | - | - |
Ad26.Mos4.HIV | Phase 3 | Healthy | - | - |
Icotrokinra | Phase 3 | Crohn Disease | - | - |
Remifentanil | Phase 3 | Anesthesia | - | - |
Pegylated interferon alfa-2a | Phase 3 | Chronic Hepatitis C Virus (HCV) Infection | - | - |
Sirukumab 50 mg | Phase 3 | Depressive Disorder, Major | - | - |
Guselkumab dose 1 | Phase 3 | Hidradenitis Suppurativa | - | - |
Aticaprant | Phase 3 | Depressive Disorder, Major | - | - |
Milvexian | Phase 3 | Acute Coronary Syndrome | - | - |
Fentanyl 1-day transdermal patch (Titration Phase) | Phase 3 | Pain | - | - |
ER OROS paliperidone | Phase 3 | Schizophrenia | - | - |
Efgartigimod | Phase 3 | Myasthenia Gravis | - | - |
Erdafitinib | Phase 3 | Advanced Solid Tumor | - | - |
rivaroxaban 15 mg | Phase 3 | Atrial Fibrillation | - | - |
Group 2 ustekinumab 130 mg | Phase 3 | Crohn's Disease | - | - |
5-Flurouracil | Phase 3 | Squamous Cell Carcinoma of Head and Neck | - | - |
CNTO 1959 50 mg | Phase 3 | Psoriasis | - | - |
ExPEC9V | Phase 3 | Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | - | - |
NUCYNTA | Phase 3 | Pain | - | - |
Paliperidone palmitate (R092670) | Phase 3 | Schizophrenia | - | - |
paliperidone palmitate injection | Phase 3 | Schizophrenia | - | - |
TAR-210 | Phase 3 | Non-Muscle Invasive Bladder Neoplasms | - | - |
Vinflunine | Phase 3 | Urothelial Cancer | - | - |
Guselkumab Dose 2 | Phase 3 | Colitis, Ulcerative | - | - |
PP3M 175 mg eq. | Phase 3 | Schizophrenia | - | - |
Ustekinumab IV | Phase 3 | Colitis, Ulcerative | - | - |
DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC | Phase 3 | HIV-1 | - | - |
Canagliflozin 100 mg | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Ad26.ZEBOV | Phase 3 | Ebola Virus Disease | - | - |
Bendamustine hydrochloride | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
R331333 (referred to as JNS024 ER or CG5503) | Phase 3 | Pain | - | - |
Genetic: AAV5-hRKp.RPGR | Phase 3 | X-Linked Retinitis Pigmentosa | - | - |
Efavirenz | Phase 3 | Human Immunodeficiency Virus-type 1 Infection | - | - |
Pegylated interferon alfa-2a (PegIFNα-2a) | Phase 3 | Hepatitis C, Chronic | - | - |
Golimumab | Phase 3 | Arthritis, Juvenile | - | - |
Guselkumab 100 mg | Phase 3 | Psoriasis | - | - |
Risankizumab | Phase 3 | Crohn Disease | - | - |
Nipocalimab | Phase 3 | Arthritis, Rheumatoid | - | - |
Telaprevir | Phase 3 | Hepatitis C, Chronic | - | - |
Pegylated interferon alpha-2a | Phase 3 | Hepatitis C Virus Genotype-1 | - | - |
ustekinumab 45 mg | Phase 3 | Arthritis, Psoriatic | - | - |
Durogesic® (fentanyl transdermal drug delivery system) | Phase 3 | Chronic Pain | - | - |
Paliperidone ER OROS® | Phase 3 | Schizophrenia | - | - |
Canagliflozin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Abiraterone acetate | Phase 3 | Prostate Neoplasms | - | - |
Ad26.ZEBOV 5*10^10 viral particles (vp) | Phase 3 | Healthy | - | - |
Intravenous immunoglobulins (IVIG) | Phase 3 | Thrombocytopenia, Neonatal Alloimmune | - | - |
methylphenidate | Phase 3 | Depressive Disorder, Major | - | - |
Sirukumab | Phase 3 | Arthritis, Rheumatoid | - | - |
Daratumumab IV | Phase 3 | Multiple Myeloma | - | - |
Paliperidone extended release (ER) | Phase 3 | Schizophrenia | - | - |
Ad26.RSV.PreF-based Vaccine | Phase 3 | Respiratory Syncytial Virus Prevention | - | - |
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF | Phase 3 | Respiratory Syncytial Viruses | - | - |
D/C/F/TAF | Phase 3 | Human Immunodeficiency Virus Type 1 | - | - |
Nesiritide | Phase 3 | Heart Decompensation | - | - |
Fumaric Acid Esters | Phase 3 | Psoriasis | - | - |
Temsirolimus | Phase 3 | Mantle Cell Lymphoma | - | - |
Sofosbuvir | Phase 3 | Chronic Hepatitis C | - | - |
Epo-alpha | Phase 3 | Resuscitation | - | - |
Tapentadol (CG5503) Extended Release (ER) | Phase 3 | Pain | - | - |
Rivaroxaban (Xarelto, BAY59-7939) | Phase 3 | Venous Thromboembolism | - | - |
Morphine | Phase 3 | Hysterectomy | - | - |
oxycodone | Phase 3 | Osteoarthritis, Knee | - | - |
Risperidone, long-acting injectable | Phase 3 | Schizophrenia | - | - |
risperidone; quetiapine | Phase 3 | Bipolar Disorder | - | - |
topiramate, propranolol | Phase 3 | Migraine | - | - |
Enoxaparin | Phase 3 | Venous Thromboembolism | - | - |
CG5503 IR | Phase 3 | Bunionectomy | - | - |
galantamine ER | Phase 3 | Alzheimer's Disease | - | - |
Test acetaminophen | Phase 3 | Post-operative Dental Pain | - | Patent 2032 |
CG 5503;tapentadol | Phase 3 | Osteoarthritis | - | - |
tapentadol (CG5503) ER | Phase 3 | Low Back Pain | - | - |
levofloxacin | Phase 3 | Pneumonia | - | |
Rivaroxaban | Phase 3 | Atrial Fibrillation | - | Patent 2034 |
tapentadol (CG5503) Immediate Release IR | Phase 3 | Low Back Pain | - | - |
Acetaminophen/Naproxen Sodium Fixed Combination | Phase 3 | Pain | - | - |
Paliperidone extended-release | Phase 3 | Bipolar Disorder | - | - |
Risperdal Consta | Phase 3 | Bipolar Disorder | - | - |
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD) | Phase 3 | Multiple Myeloma | - | - |
paliperidone ER Oros | Phase 3 | Schizophrenia | - | |
Gemcitabine with R115777 | Phase 3 | Pancreatic Neoplasms | - | - |
Mebendazole | Phase 3 | Healthy Volunteers | - | |
Dapoxetine | Phase 3 | Erectile Dysfunction | - | - |
F# 13418-148 Eye Drops | Phase 3 | Ophthalmic Solutions | - | - |
Rivaroxaban 2.5 mg | Phase 3 | Acute Coronary Syndrome | - | Patent 2034 |
Paliperidone ER | Phase 3 | Schizophrenia | - | |
topiramate | Phase 3 | Essential Tremor | - | Patent 2040 |
doripenem | Phase 3 | Pneumonia | - | |
norelgestromin + ethinyl estradiol | Phase 3 | Contraception | - | - |
Rabeprazole sodium 5 mg | Phase 3 | Gastroesophageal Reflux | - | |
Tapentadol extended release (ER) | Phase 3 | Diabetic Peripheral Neuropathy | - | - |
Thalidomide | Phase 3 | Multiple Myeloma | - | - |
CG5503 IR;tapentadol | Phase 3 | Arthralgia | - | - |
Topiramate; Carbamazepine; Valproate | Phase 3 | Epilepsy | - | - |
levofloxacin; imipenem/cilastitin | Phase 3 | Nosocomial Pneumonia | - | - |
Pancrease MT 10.5, or MT 21 | Phase 3 | Exocrine Pancreatic Insufficiency | - | - |
Colloidal Oatmeal Cream | Phase 3 | Eczema | - | - |
ivermectin | Phase 3 | Lice Infestations | - | - |
Paliperidone palmitate 25 mg eq. | Phase 3 | Schizophrenia | - | - |
JNJ-90301900 (NBTXR3) | Phase 3 | Locally Advanced Head and Neck Squamous Cell Carcinoma | - | - |
norelgestromin + ethinyl estradiol; mercilon | Phase 3 | Contraception | - | - |
Extended-release galantamine hydrobromide | Phase 3 | Schizophrenia | - | - |
Test naproxen sodium tablet | Phase 3 | Post-operative Dental Pain | - | - |
galantamine | Phase 3 | Alzheimer's Disease | - | - |
5% Minoxidil Topical Foam | Phase 3 | Androgenetic Alopecia | - | - |
Imonogas | Phase 3 | Functional Dyspepsia | - | - |
rabeprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
galantamine hydrobromide | Phase 3 | Alzheimer Disease | - | - |
Hydromorphone HCl | Phase 3 | Pain | - | - |
topiramate, phenytoin | Phase 3 | Epilepsy | - | - |
Paliperidone palmitate | Phase 3 | Schizophrenia | - | - |
norelgestromin + ethinyl estradiol; triphasil. | Phase 3 | Contraception | - | - |
doripenum | Phase 3 | Urinary Tract Infections | - | - |
acetaminophen extended release | Phase 3 | Osteoarthritis | - | - |
CG5503 | Phase 3 | Diabetic Neuropathy | - | - |
Duragesic® (fentanyl) Therapeutic Transdermal System (TTS) | Phase 3 | Chronic Pain | - | - |
CG5503 IR; tapentadol | Phase 3 | Osteoarthritis | - | - |
5% Minoxidil | Phase 3 | Alopecia | - | - |
naproxen | Phase 3 | Osteoarthritis, Hip | - | - |
minoxidil | Phase 3 | Androgenetic Alopecia | - | - |
PDE5I (phosphodiesterase-5 inhibitor) | Phase 3 | Erectile Dysfunction | - | - |
Extended Release OROS® Paliperidone | Phase 3 | Schizophrenia | - | - |
acetaminophen Tablet | Phase 3 | Post Operative Dental Pain | - | - |
Paliperidone | Phase 3 | Schizophrenia | - | - |
Tipifarnib;Zarnestra; R115777 | Phase 3 | Acute Myeloid Leukemia | - | - |
Epoetin alfa 3 times weekly /once weekly | Phase 3 | Anemia | - | - |
epoetin alfa | Phase 3 | Chronic Kidney Disease | - | - |
Prucalopride | Phase 3 | Constipation | - | - |
Ibrutinib | Phase 3 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
TAR-200 | Phase 3 | Non-Muscle Invasive Bladder Neoplasms | - | - |
Levetiracetam | Phase 3 | Epilepsy | - | - |
Cilta-cel | Phase 3 | Multiple Myeloma | - | - |
Talquetamab | Phase 3 | Multiple Myeloma | - | - |
TMC435 | Phase 3 | Hepatitis C | - | - |
JNJ-77242113 | Phase 3 | Plaque Psoriasis | - | - |
Simeprevir | Phase 3 | Hepatitis C Virus Infection | - | - |
Fentanyl | Phase 3 | Postherpetic Neuralgia | - | - |
No treatment | Phase 3 | Hepatitis C | - | - |
JNJ-63723283 | Phase 3 | Multiple Myeloma | - | - |
Guselkumab | Phase 3 | Psoriasis | - | - |
Daratumumab | Phase 3 | Multiple Myeloma | - | - |
Fulranumab 1 mg | Phase 3 | Osteoarthritis | - | - |
Ad26.COV2.S | Phase 3 | Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol | - | - |
Macitentan | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Rilpivirine | Phase 3 | HIV-1 | - | - |
Amivantamab | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Sirukumab 100 mg | Phase 3 | Arthritis, Rheumatoid | - | - |
Seltorexant | Phase 3 | Depressive Disorder, Major | - | - |
Ustekinumab | Phase 3 | Crohn Disease | - | - |
Teclistamab | Phase 3 | Multiple Myeloma | - | - |
R228060 | Phase 2 | Major Depressive Disorder | - | - |
Antipsychotic medication | Phase 2 | Schizophrenia | - | - |
Daratumumab 16 mg/kg (Part 1) | Phase 2 | Multiple Myeloma | - | - |
Escitalopram | Phase 2 | Major Depressive Disorder | - | - |
JNJ-90301900 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Experimental Product 1% Colloidal Oatmeal Balm | Phase 2 | Atopic Dermatitis | - | - |
Lymphodepleting Therapy (Cyclophosphamide and Fludarabine) | Phase 2 | Multiple Myeloma | - | - |
JNJ16269110 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Canagliflozin (JNJ-28431754) | Phase 2 | Diabetes Mellitus, Type II | - | - |
ibuprofen; pseudoephedrine HCl | Phase 2 | Enuresis | - | - |
RWJ-445380 100 mg | Phase 2 | Rheumatoid Arthritis | - | - |
Capmatinib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
CNTO 1959 | Phase 2 | Palmoplantaris Pustulosis | - | - |
Nesiritide (1+0.01) | Phase 2 | Heart Failure, Congestive | - | - |
Erdafitinib Intravesical Delivery System | Phase 2 | Non-Muscle Invasive Bladder Neoplasms | - | - |
Ad26.RSV.preF (1*10^11 vp) | Phase 2 | Respiratory Syncytial Viruses | - | - |
JNJ-40411813 | Phase 2 | Major Depressive Disorder | - | - |
tapentadol HCl | Phase 2 | Pain | - | - |
Abiraterone | Phase 2 | Prostate Cancer | - | - |
ET743 | Phase 2 | Breast Neoplasms | - | - |
JNJ-37822681 | Phase 2 | Schizophrenia | - | - |
JNJ-64565111 Dose Level 1 | Phase 2 | Obesity and Diabetes Mellitus, Type 2 | - | - |
Canagliflozin 50 mg | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
JNJ-63623872 | Phase 2 | Influenza A Virus | - | - |
AL-335 | Phase 2 | Hepatitis C, Chronic | - | - |
R092670 | Phase 2 | Schizophrenia | - | - |
JNJ-73763989 | Phase 2 | Hepatitis B, Chronic | - | - |
Siltuximab | Phase 2 | Multicentric Castleman's Disease | - | - |
JNJ-40346527 | Phase 2 | Arthritis, Rheumatoid | - | - |
JNJ-41443532 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
JNJ-64304500 | Phase 2 | Crohn Disease | - | - |
JNJ-39588146 5 ng/kg/min | Phase 2 | Heart Failure | - | - |
tipifarnib (R115777) | Phase 2 | Leukemia, Nonlymphocytic, Acute | - | - |
JNJ39758979 | Phase 2 | Asthma | - | - |
NNC0142-0002 | Phase 2 | Inflammation | - | - |
RSV Vaccine | Phase 2 | Healthy | - | - |
NNC 0142-0000-0002 | Phase 2 | Inflammation | - | - |
Imipenem/cilastatin | Phase 2 | Pneumonia, Ventilator-Associated | - | - |
JNJ-31001074 | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
T2-18C3 therapeutic antibody | Phase 2 | Type 2 Diabetes | - | - |
Tapentadol | Phase 2 | Pain | - | - |
Amivantamab IV | Phase 2 | Advanced or Metastatic Colorectal Cancer | - | - |
JNJ 40929837 | Phase 2 | Asthma | - | - |
Glucocorticoids | Phase 2 | Myositis | - | - |
R209130 | Phase 2 | Schizophrenia | - | - |
Ketoconazole | Phase 2 | Neoplasm Metastases | - | - |
CNTO 2476 3.0 x 10^5 cells | Phase 2 | Visual Acuity | - | - |
Fluarix | Phase 2 | Healthy | - | - |
R256918 | Phase 2 | Obesity | - | - |
Apalutamide | Phase 2 | Salivary Gland Neoplasms | - | - |
ZARNESTRA, tipifarnib, R115777 | Phase 2 | Acute Myeloid Leukemia | - | - |
VX-787 300 mg | Phase 2 | Influenza A | - | - |
Daratumumab Injection | Phase 2 | Plasma Cell Disorder | - | - |
JNJ-17166864 | Phase 2 | Allergic Rhinitis | - | - |
Acetaminophen (ACE) (1000 mg) | Phase 2 | Dental Pain | - | - |
JNJ-81201887 | Phase 2 | Geographic Atrophy | - | - |
Acetaminophen | Phase 2 | Post Operative Analgesia | - | - |
Olomorasib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Ad26.RSV.preF | Phase 2 | Respiratory Syncytial Virus | - | - |
VELCADE | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
PROCRIT (Epoetin alfa) | Phase 2 | Anemia | - | - |
Cetrelimab | Phase 2 | Urinary Bladder Neoplasms | - | - |
sIPV | Phase 2 | Healthy | - | - |
Ad26.Mos.HIV | Phase 2 | Healthy | - | - |
MVA-Mosaic | Phase 2 | Human Immunodeficiency Virus | - | - |
JNJ-53718678 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
Blink® Tears eye drops in a multidose bottle | Phase 2 | Visual Acuity | - | - |
TMC207 (bedaquiline) | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
JNJ-42165279 | Phase 2 | Depressive Disorder | - | - |
JNJ-42847922 | Phase 2 | Depressive Disorder, Major | - | - |
440 mg naproxen sodium with 1000 mg acetaminophen | Phase 2 | Pain | - | - |
JNJ-26489112 | Phase 2 | Photosensitive Epilepsy | - | - |
Atomoxetine 80 mg/d | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
Acetaminophen/naproxen sodium Dose A | Phase 2 | Pain | - | - |
Investigational Lubricating Eye Drop in a Novelia® bottle | Phase 2 | Dry Eye | - | - |
JNJ-39220675 | Phase 2 | Allergic Rhinitis | - | - |
Standard-of-care treatment | Phase 2 | Systemic Lupus Erythematosus | - | - |
Yondelis | Phase 2 | Liposarcoma | - | - |
Atazanavir (ATV) 300 mg | Phase 2 | HIV Infections | - | - |
JNJ 49095397 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
ExPEC4V (4 : 4 : 4 : 4) | Phase 2 | Healthy | - | - |
Schizophrenia
4 drugs in this indication
Bipolar Disorder
3 drugs in this indication
Pain
2 drugs in this indication
Multiple Myeloma
2 drugs in this indication
Pneumonia
2 drugs in this indication
Diabetes Mellitus, Type 2
2 drugs in this indication
Low Back Pain
2 drugs in this indication
Pain relief
2 drugs in this indication
Major Depressive Disorder
1 drug in this indication
Ophthalmic Solutions
1 drug in this indication
Acute Coronary Syndrome
1 drug in this indication
Contraception
1 drug in this indication
Post-operative Dental Pain
1 drug in this indication
Chronic Kidney Disease
1 drug in this indication
Healthy Volunteers
1 drug in this indication
Osteoarthritis
1 drug in this indication
Erectile Dysfunction
1 drug in this indication
Atrial Fibrillation
1 drug in this indication
Alzheimer's Disease
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Enuresis
1 drug in this indication
Pancreatic Neoplasms
1 drug in this indication
Gastroesophageal Reflux
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Essential Tremor
1 drug in this indication
recurrent or metastatic head and neck cancer
1 drug in this indication
Sprains and Strains
1 drug in this indication
Diabetic Peripheral Neuropathy
1 drug in this indication
Heart Failure
1 drug in this indication
SLE (Systemic Lupus Erythematosus)
1 drug in this indication
depression
1 drug in this indication
Leukemia, Nonlymphocytic, Acute
1 drug in this indication
over-the-counter treatment of pain
1 drug in this indication
Asthma
1 drug in this indication
relapsed/refractory multiple myeloma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Johnson & Johnson's drug pipeline?→
CatalystAlert tracks 244 drug candidates in Johnson & Johnson's (JNJ) pipeline across Phase 3, Phase 2. Its lead program is oxycodone CR (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Johnson & Johnson's next FDA catalyst?→
Johnson & Johnson's (JNJ) next tracked catalyst is a Phase 2 expected April 27, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JNJ biotech catalysts?→
Add JNJ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Johnson & Johnson's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.